Single Drug Tear Sheet
$500
Peer Comparison Add-On
$750
HTA + Policy Calendar add-on
Contact Us for
Custom Pricing
custom scenario simulator
Contact Us for
Custom Pricing
live strategy briefing
Contact Us for
Custom Pricing
AI Validation services
Contact Us for
Custom Pricing
Have a pricing strategy question or evaluating an AI deployment?
Submit your questionTrouble opening the form? Tap here to open it directly.
Sign up to receive the latest from AureusIQ — including new drug pricing reports, policy insights and early updates on the AI tools we're building.
Subscribe NowTrouble subscribing? Click here to open the form.
AureusIQ provides independent economic evaluation for complex healthcare decisions.
We specialize in pharmaceutical pricing strategy and AI workflow economics, combining health economic modeling with structured policy and operational analysis.
Our focus is simple: deliver clear, defensible insights that support high-stakes decision-making under uncertainty.
Why the name "AureusIQ"?
The name AureusIQ was inspired by the Latin word "Aureus", meaning "golden", signifying value that endures. It reflects the clarity, precision, and integrity we aim to deliver in an increasingly chaotic world we are living in, where these qualities are becoming rare. The “IQ” signifies not just intelligence, but Insight Quality—representing our signal over noise approach that ensures every piece of intelligence we provide is actionable, relevant, and of the highest quality you can trust. We are committed to delivering insights that you can depend on, providing the foundation for informed, confident decision-making in today’s complex and evolving market.
We offer a modern approach to pharma intelligence, one that is more responsive, smarter, and more flexible so you can stay ahead of the curve.
Learn more about our vision for our future here.
Cloe Koh is a seasoned healthcare operator with a deep background in pharmacy and broad expertise in drug pricing, market access, and regulatory strategy across both public and private sectors. Trained as a pharmacist, she played a key role in national drug pricing benchmarking initiatives at Singapore’s Ministry of Health. At UnitedHealthcare/Optum, she led analytics efforts supporting senior leadership on Medicare Part B drug reimbursement strategy and financial risk, providing a data-driven lens into payer decision-making at scale.
As founder and CEO of AureusIQ, Cloe drives the development of MFN analytical products used by HEOR, market access, strategy teams, and healthcare investors to assess exposure to pricing regulation and policy-driven shifts across therapeutic categories. She is also spearheading the buildout of AI-powered tools that accelerate evidence synthesis and decision-making in complex regulatory environments. Her work sits at the intersection of policy, pricing, and data science, turning fragmented guidance into actionable insight. She brings a rare combination of clinical grounding, strategic clarity, and operational execution to one of healthcare’s most dynamic and high-stakes domains.
Dr. Mark Dranias is a computational neuroscientist and AI expert with over two decades of interdisciplinary experience spanning neuroscience, data science, computer vision, and large language models (LLMs). He brings deep academic and industry expertise to AureusIQ, driving the company’s AI strategy and end-to-end product architecture.
At AureusIQ, Dr. Dranias leads development and delivery of AI validation services and products. His work enables pharma, HEOR and market access teams to extract insights from vast, unstructured sources including clinical literature, policy guidelines, and pricing databases with speed and precision. He has built scalable, full-stack AI systems that integrate natural language processing, multimodal data analysis, and workflow automation to streamline decision-making across the healthcare value chain.
